Jaguar Health (JAGX) Accounts Payables (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Accounts Payables of $5.0 million for Q1 2026, down 29.47% year-over-year from $7.0 million in Q1 2025, and down 42.93% quarter-over-quarter from $8.7 million in Q4 2025.
Jaguar Health (JAGX) Accounts Payables (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Accounts Payables for 13 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 29.47% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (down 29.47% YoY), while the FY2025 annual figure was $8.7 million, up 64.32% from the prior year.
- Accounts Payables declined to $5.0 million in Q1 2026 per JAGX's latest filing, from $8.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $8.7 million in Q4 2025 and bottomed at $3.3 million in Q1 2024.
- Historically, Accounts Payables has averaged $5.6 million across 5 years, with a median of $5.3 million in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables slumped 41.67% — and 2025, when it soared 111.69%.
- Jaguar Health's Accounts Payables stood at $5.8 million in 2022, then declined by 14.36% to $5.0 million in 2023, then advanced by 6.27% to $5.3 million in 2024, then surged by 64.32% to $8.7 million in 2025, then sank by 42.93% to $5.0 million in 2026.
- Business Quant data shows JAGX's Accounts Payables at $5.0 million in Q1 2026, $8.7 million in Q4 2025, and $8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 4.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.96 Mn |
| Dec 31, 2025 | 8.69 Mn |
| Sep 30, 2025 | 8.44 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 7.03 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 4.55 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 3.32 Mn |
| Dec 31, 2023 | 4.97 Mn |
| Sep 30, 2023 | 5.13 Mn |
| Jun 30, 2023 | 4.66 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | 6.29 Mn |
| Jun 30, 2022 | 5.65 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.93 Mn |
| Sep 30, 2021 | 3.79 Mn |
| Jun 30, 2021 | 4.92 Mn |